Gilead

August 31, 2017

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
August 23, 2016

Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation […]